Identification of critical process parameters for expansion of clinical grade human Wharton's jelly‐derived mesenchymal stromal cells in stirred‐tank bioreactors
Biotechnology Journal · 2024
DOI: 10.1002/biot.202300381 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Journal, 2024. Verfasst von Alba López-Fernández und 3 weiteren Autor:innen. Beteiligte Einrichtung: Servei de Teràpia Cel·lular i Avançada, Banc de Sang i Teixits, Edifici Dr. Frederic Duran i Jordà, Barcelona, Spain. Hauptthemen laut MEDLINE: Wharton Jelly, Mesenchymal Stem Cells. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Departament d'Universitats i Recerca, European Social Funds, Banc de Sang i Teixits.
Abstract (Originalsprache)
Cell therapies based on multipotent mesenchymal stromal cells (MSCs) are traditionally produced using 2D culture systems and platelet lysate‐ or serum‐containing media (SCM). Although cost‐effective for single‐dose autologous treatments, this approach is not suitable for larger scale manufacturing (e.g., multiple‐dose autologous or allogeneic therapies with banked MSCs); automated, scalable and Good Manufacturing Practices (GMP)‐compliant platforms are urgently needed. The feasibility of transitioning was evaluated from an established Wharton's jelly MSCs (WJ‐MSCs) 2D production strategy to a new one with stirred‐tank bioreactors (STRs). Experimental conditions included four GMP‐compliant xeno‐ and serum‐free media (XSFM) screened in 2D conditions and two GMP‐grade microcarriers assessed in 0.25 L‐STRs using SCM. From the screening, a XSFM was selected and compared against SCM using the best‐performing microcarrier. It was observed that SCM outperformed the 2D‐selected medium in STRs, reinforcing the importance of 2D‐to‐3D transition studies before translation into clinical production settings. It was also found that attachment efficiency and microcarrier colonization were essential to attain higher fold expansions, and were therefore defined as critical process parameters. Nevertheless, WJ‐MSCs were readily expanded in STRs with both media, preserving critical quality attributes in terms of identity, viability and differentiation potency, and yielding up to 1.47 × 10 9 cells in a real‐scale 2.4‐L batch.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servei de Teràpia Cel·lular i Avançada, Banc de Sang i Teixits, Edifici Dr. Frederic Duran i Jordà, Barcelona, Spain.
- Engineering Materials Group (GEMAT), Bioprocessing Lab, IQS School of Engineering, Universitat Ramón Llull, Barcelona, Spain.
- Musculoskeletal Tissue Engineering Group, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
- Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
ORCID-Profile: Alba López-Fernández, Víctor Garcia-Gragera, Martí Lecina, Joaquim Vives
Förderung
- Departament d'Universitats i Recerca
- European Social Funds
- Banc de Sang i Teixits
- Instituto de Salud Carlos III (ISCIII)
Zitieren
APA
López-Fernández, A., Garcia-Gragera, V., Lecina, M., & Vives, J. (2024). Identification of critical process parameters for expansion of clinical grade human Wharton's jelly‐derived mesenchymal stromal cells in stirred‐tank bioreactors. Biotechnology Journal. https://doi.org/10.1002/biot.202300381
Vancouver
López-Fernández A, Garcia-Gragera V, Lecina M, Vives J. Identification of critical process parameters for expansion of clinical grade human Wharton's jelly‐derived mesenchymal stromal cells in stirred‐tank bioreactors. Biotechnology Journal. 2024. doi:10.1002/biot.202300381
BibTeX
@article{LpezFernndez2024,
author = {López-Fernández, Alba and Garcia-Gragera, Víctor and Lecina, Martí and Vives, Joaquim},
title = {Identification of critical process parameters for expansion of clinical grade human Wharton's jelly‐derived mesenchymal stromal cells in stirred‐tank bioreactors},
journal = {Biotechnology Journal},
year = {2024},
doi = {10.1002/biot.202300381}
}
EUVIMED